1-2 of 2
Anne Parker
Close
Sort by
Journal Articles

Venetoclax–based low intensity therapy in molecular failure of NPM1 -mutated AML

Clinical Trials & Observations
Carlos Jimenez-Chillon, Jad Othman, David Taussig, Carlos Jimenez-Vicente, Alexandra Martinez-Roca, Ing Soo Tiong, Manish Jain, James Aries, Seda Cakmak, Steven Knapper, Daniel Tuyet Kristensen, Vidhya Murthy, Joy Zacharoula Galani, Charlotte Kallmeyer, Loretta Ngu, David Veale, Simon Bolam, Nina Orfali, Anne Parker, Cara Manson, Jane Parker, Thomas Erblich, Deborah Richardson, Katya Mokretar, Nicola Potter, Ulrik Malthe Overgaard, Anne Stidsholt Roug, Andrew H. Wei, Jordi Esteve, Martin Jädersten, Nigel Russell, Richard Dillon
Journal: Blood Advances
Blood Adv (2024) 8 (2): 343–352.
https://doi.org/10.1182/bloodadvances.2023011106
Published: 2024
Includes: Supplemental data
Journal Articles

Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting

Maria A. V. Marzolini, Varun Mehra, Kirsty J. Thomson, Eleni Tholouli, Adrian J. C. Bloor, Anne Parker, Richard Lovell, Kim Orchard, Amy Publicover, Emma Nicholson, John A. Snowden, Jennifer Byrne, Anjum Khan, Maria H. Gilleece, Gerardo Errico, Sara Lozano, Erin Hurst, Nick Duncan, Jennifer Pirrie, Philip Crea, Ben Carpenter, Antonio Pagliuca, Karl S. Peggs
Journal: Blood Advances
Blood Adv (2021) 5 (21): 4500–4503.
https://doi.org/10.1182/bloodadvances.2021005637
Published: 2021